Gregory J. Divis - Dec 7, 2021 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role
Chief Executive Officer, Director
Signature
/s/ Jerad Seurer, as Attorney-in-Fact
Stock symbol
AVDL
Transactions as of
Dec 7, 2021
Transactions value $
$0
Form type
4
Date filed
12/9/2021, 05:45 PM
Previous filing
May 20, 2021
Next filing
Mar 30, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVDL Stock Option (Right to Buy) Award $0 +310K $0.00 310K Dec 7, 2021 ADSs 310K $8.20 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options become exercisable as to 77,500 ADSs on each of the first four anniversaries after the 12/07/2021 grant date.
F2 The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.